Trial · NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
NCT07497386, Phase 2, Recruiting, Jiangsu HengRui Medicine Co., Ltd.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer. Trials, record NCT07497386. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07497386
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
- NCT number
- NCT07497386
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Conditions
- Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
- Interventions
- Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection
- First posted
- 2026-03-27
- Last updated
- 2026-05-11
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS). | Every 6 weeks after administration, approximately 14 months. | |
| Secondary | Objective response rate (ORR). | Every 6 weeks after administration, approximately 14 months. | |
| Secondary | Duration of response (DoR). | Every 6 weeks after administration, approximately 14 months. | |
| Secondary | Clinical benefit rate (CBR). | Every 6 weeks after administration, approximately 14 months. | |
| Secondary | Adverse events (AEs). | From the first dose administration until 40 days after the last dose administration. | Graded according to NCI-CTCAE version 5.0. |
| Secondary | Laboratory test indicators, including complete blood count. | From the first dose administration until 40 days after the last dose administration. | |
| Secondary | Laboratory test indicators, including urinalysis. | From the first dose administration until 40 days after the last dose administration. | |
| Secondary | Laboratory test indicators, including virology screening. | From the first dose administration until 40 days after the last dose administration. | |
| Secondary | Serum concentrations of Trastuzumab Rezetecan. | Until the end of treatment, approximately 14 months. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07497386
GET https://conductscience.org/api/trials/v1/NCT07497386/registered